GPhA OUTLINES AGENDA FOR NEW FDA COMMISSIONER

JULY 01, 2006

Officials at the Generic Pharmaceutical Association (GPhA) are wasting no time in letting incoming FDA Commissioner Andrew von Eschenbach, MD, know what they will be expecting from him. In a statement welcoming Dr. von Eschenbach to the FDA, GPhA President and Chief Executive Officer Kathleen Jaeger said that the appointment of "a permanent commissioner is an absolute necessity at a federal agency that has such a direct impact on the health and well-being of America's citizens."

Jaeger urged the new FDA chief to move quickly "to appropriately address important issues, such as an abbreviated approval pathway for generic biopharmaceuticals, authorized generics, the timely approval of generic medicines, and increased funding for the Office of Generic Drugs."




SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.